Last Updated: 5/16/2010

C. Ryan Miller, MD, PhD

Assistant Professor
Clinical Research

Clinical Interests
Surgical neuropathology

Research Interests
Diffuse gliomas are a diverse group of primary brain tumors. The most malignant of these, glioblastoma (GBM), is currently diagnosed by microscopic morphology and treated empirically with concurrent fractionated external beam radiation (XRT) and the DNA alkylating agent temozolomide (TMZ) to yield a median overall survival of 12-14 months. Neither diagnosis nor therapy is based upon the underlying molecular alterations responsible for gliomagenesis, the roles of which are becoming increasingly defined through the use of genetically-engineered mouse models (GEMM). The main goal of our work is to establish a direct link between preclinical drug development in GBM GEMM and the rational design of human clinical trials involving patients with molecular subtypes of GBM through use of comparative molecular analyses to
1) molecularly stratify human GBM with distinct responses to chemoradiation;
2) define the roles of cell-of-origin and genetics in GEM GBM subtype-specification; and
3) define molecular signatures of TMZ-XRT-resistant GEM and recurrent human GBM.

Recent Accomplishments and Honors
2009 Damon Runyon-Genentech Clinical Scholar, Damon Runyon Cancer Research Foundation

2007 Member, Glioblastoma Disease Working Group, The Cancer Genome Atlas (TCGA) Project, National Cancer Institute

2007 American Association of Neuropathologists Moore Award

2007 American Association of Neuropathologists Merit Award

2006 American Society of Clinical Oncology Merit Award

2005 American Association of Neuropathologists Merit Award

2000 American Brain Tumor Association Lucien J. Rubenstein Award for Outstanding Brain Tumor Research

Washington University School of Medicine, St. Louis, Missouri
Barnes-Jewish Hospital
Neuropathology Fellowship, June 2006

Washington University School of Medicine, St. Louis, Missouri
Barnes-Jewish Hospital
Anatomic Pathology Residency, June 2004

University of Alabama School of Medicine (UASOM), Birmingham, Alabama
Doctor of Medicine (MD), June 2002
Medical Scientist Training (MD/PhD) Program

University of Alabama at Birmingham (UAB), Birmingham, Alabama
Doctor of Philosophy (PhD), June 1999
Department of Pathology, Division of Cellular and Molecular Pathology

Vanderbilt University, Nashville, Tennessee
Bachelor of Arts, Summa Cum Laude, May 1992
Phi Beta Kappa, Honors in the College of Arts & Science
Majors: Chemistry and Mathematics

Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN and the Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17(1):98 Jan 2010. PMID: 20129251
Goodgame B, Viswanathan A, Zoole J, Gao F, Miller CR, Subramanian J, Meyers BF, Patterson GA, Govindan R. Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients. Journal of Thoracic Oncology. 4(11):1370 Nov 2009. PMID: 19692932

Perry A, Miller CR, Gujrati M, Scheithauer BW, Jost SC, Raghavan R, Qian J, Cochran EJ, Huse JT, Holland EC, Burger PC, Rosenblum MK. Malignant gliomas with neuroblastic (PNET-like) components (GBM-PNET): A clinicopathologic and genetic study of 52 cases. Brain Pathology. 19(1):81 Jan 2009. PMID: 18452568

Goodgame B, Viswanathan A, Miller CR, Gao F, Meyers B, Battafarano RJ, Patterson A, Cooper J, Guthrie TJ, Bradley J, Pillot G, Govindan R. A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer. Am J Clin Oncol 31(1):22 Feb 2008.
Miller CR and Perry A. Glioblastoma: Morphological and molecular genetic
diversity. Archives of Pathology and Laboratory Medicine. 131(3):397-406. Mar 2007. Review article.

Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod HL. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep. 17(4):853-7 Apr 2007.

Miller CR and McLeod HL. Pharmacogenomics of cancer chemotherapy-related
toxicity. Journal of Supportive Oncology. 5(1):9 Jan 2007. Review article.

Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Piwnica-Worms D,
Rich KM. Tissue transglutaminase 2 inhibitor, KCC009, disrupts fibronectin
assembly in the extracellular matrix and sensitizes orthotopic glioblastomas
to chemotherapy. Oncogene. 26(18):2563 Apr 2007.

Miller CR, Dunham C, Scheithauer B, Perry A. Significance of necrosis in
grading of oligodendroglial neoplasms: A clinicopathological and genetic
study of 1093 high-grade gliomas. Journal of Clinical Oncology.
24(34):5419 Dec 2006.

Conrad CA, Miller CR, Ji Y, Gumin J, Gomez-Manzano C, Bharara S, McMurray
JS, Lang FF, Wong F, Sawaya R, Yung WKA, Fueyo J. Δ24-hyCD adenovirus
suppresses glioma growth in vivo by combining oncolysis and
chemosensitization. Cancer Gene Therapy 12(3):284 Mar 2005.

Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral
5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy
is effective for experimental human glioblastomas. Cancer Research
62(3):773 Feb 2002.

Click here for a list of Publications on PubMed

Telephone: 966-4333
FAX: 966-6718
Address: 6109B Neurosciences Research Building Chapel Hill, NC 27599-7250

Click here to update this profile